These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33105541)

  • 61. Lessons learned from routine, targeted assessment of liquid biopsies for
    Mondaca S; Offin M; Borsu L; Myers M; Josyula S; Makhnin A; Shen R; Riely GJ; Rudin CM; Ladanyi M; Yu HA; Li BT; Arcila ME
    Acta Oncol; 2019 Nov; 58(11):1634-1639. PubMed ID: 31347936
    [No Abstract]   [Full Text] [Related]  

  • 62. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 64. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.
    Qvick A; Stenmark B; Carlsson J; Isaksson J; Karlsson C; Helenius G
    Mol Med; 2021 Jul; 27(1):68. PubMed ID: 34217228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
    Kulasinghe A; O'Leary C; Monkman J; Bharti V; Irwin D; Dutta S; Richard DJ; Hughes B; Ladwa R; O'Byrne K
    Lung Cancer; 2021 Oct; 160():73-77. PubMed ID: 34455214
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients.
    Peng H; Lu L; Zhou Z; Liu J; Zhang D; Nan K; Zhao X; Li F; Tian L; Dong H; Yao Y
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31739500
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.
    Ryu WK; Oh S; Lim JH; Lee SJ; Shin HT; Ryu JS
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076922
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
    Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
    Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol.
    Gao Z; Shang Y; Wang X; Ma Y; Yang F; Wang J; Chen K; Zhang Y
    Thorac Cancer; 2019 May; 10(5):1310-1315. PubMed ID: 30980496
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Zhu YJ; Zhang HB; Liu YH; Zhang FL; Zhu YZ; Li Y; Bai JP; Liu LR; Qu YC; Qu X; Chen X; Li Y; Zheng GJ
    Lung Cancer; 2017 Jul; 109():124-127. PubMed ID: 28577941
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
    Plagnol V; Woodhouse S; Howarth K; Lensing S; Smith M; Epstein M; Madi M; Smalley S; Leroy C; Hinton J; de Kievit F; Musgrave-Brown E; Herd C; Baker-Neblett K; Brennan W; Dimitrov P; Campbell N; Morris C; Rosenfeld N; Clark J; Gale D; Platt J; Calaway J; Jones G; Forshew T
    PLoS One; 2018; 13(3):e0193802. PubMed ID: 29543828
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
    Tchekmedyian N; Mudad R; Blanco FF; Raymond VM; Garst J; Erlander MG; Haura E; Berz D
    Lung Cancer; 2017 Jun; 108():22-28. PubMed ID: 28625639
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
    Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
    Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clonal Architecture of
    Ai X; Cui J; Zhang J; Chen R; Lin W; Xie C; Liu A; Zhang J; Yang W; Hu X; Hu X; Zhao Q; Rao C; Zang YS; Ning R; Li P; Chang L; Yi X; Lu S
    Clin Cancer Res; 2021 Feb; 27(3):704-712. PubMed ID: 33188140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.